GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
G

Guided Therapeutics GTHP · USD

Health Care · US listing · 🇺🇸 United States

Compare

0.11

+10.00%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Guided Therapeutics

From its filings with the US Securities and Exchange Commission

SEC filings

Guided Therapeutics is based in Peachtree Corners, Georgia and is incorporated in Delaware. Its shares trade on OTC under the ticker GTHP. The SEC classifies its business as electromedical & electrotherapeutic apparatus. In the fiscal year to 31 December 2025, it reported revenue of $767,000 and a net loss of $3.2m. At that date it held total assets of $1.3m and shareholders' equity of −$6.0m.

In its own words

We are a medical technology company focused on developing innovative medical devices that have the potential to improve healthcare. Our primary focus is the sales and marketing of our LuViva® Advanced Cervical Scan non-invasive cervical cancer detection device. The underlying technology of LuViva primarily relates to the use of biophotonics for the non-invasive detection of cancers. LuViva is designed to identify cervical cancers and precancers painlessly, non-invasively and at the point of care by scanning the cervix with light, then analyzing the reflected and fluorescent light.

LuViva is designed to provide a less invasive and painless alternative to conventional tests for cervical cancer screening and detection. Additionally, LuViva is designed to improve patient well-being not only because it eliminates pain, but also because it is convenient to use and provides rapid results at the point of care. We focus on two primary applications for LuViva: first, as a cancer screening tool in the developing world, where infrastructure to support traditional cancer-screening methods is limited or non-existent, and second, as a triage following traditional screening in the developed world, where a high number of false positive results cause a high rate of unnecessary and ultimately costly follow-up tests.

Quoted from its 10-K, filed 31 Mar 2026. Read the filing on SEC.gov ↗

Company facts

Sector
Health Care
Industry
Health Care Equipment & Supplies
Listed since
1 Jul 1997
Employees
6
Head office
5835 PEACHTREE CORNERS EAST, PEACHTREE CORNERS, GA, 30092
Incorporated in
DE
Classification
Electromedical & Electrotherapeutic Apparatus
Filer status
Non-accelerated filer<br>Smaller reporting company

Leadership

Pay as last reported

  • Mr. Michael JamesIndependent Chairman of the Board
  • Dr. Mark FaupelPresident, Chief Executive Officer, Acting Chief Financial Officer, Chief Operating Officer, Director, since 2001$46,912
  • Dr. Gene CartwrightActing Chief Financial Officer, since 2014$12,000
  • Mr. Richard BlumbergDirector
  • Mr. Alan GrujicDirector
  • Dr. John ImhoffIndependent Director

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Company employs 6 full-time employees
  • Headquartered in Norcross, Georgia
  • Focuses on developing medical devices with biophotonic technology

Weaknesses

  • Limited clinical studies conducted
  • Small employee count indicates limited resources
  • Relies on a single product, LuViva, for primary revenue

Opportunities

  • Potential for expansion in cervical cancer screening market
  • Biophotonics technology could be applied to other cancer detection areas
  • Growing demand for non-invasive medical devices

Threats

  • Dependence on a single product, LuViva, for revenue
  • Limited clinical studies may hinder regulatory approvals
  • Competition in the medical device industry

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.